Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: the phase 3 randomized SUNLIGHT study

被引：0
|
作者：
Modest, D. P. [1 ]
Tabernero, J. [2 ]
Prager, G. [3 ]
Fakih, M. [4 ]
Ciardiello, F. [5 ]
Van Cutsem, E. [6 ,7 ]
Elez, E. [2 ]
Cruz, F. [8 ]
Wyrwicz, L. [9 ]
Stroyakovskiy, D. [10 ]
Papai, Z. [11 ]
Poureau, P. -G. [12 ]
Liposits, G. [13 ]
Cremolini, C. [14 ]
Benhadji, K. [15 ]
Bondarenko, I. [16 ]
Skanji, D. [17 ]
Roby, L. [17 ]
Amellal, N. [17 ]
Taieb, J. [18 ]
机构：
[1] Charite, Hamatol Onkol & Tumorimmunol, Berlin, Germany
[2] Vall dHebron Univ Hosp & Inst Oncol VHIO, UVic UCC, IOB Quiron, Barcelona, Spain
[3] Med Univ Vienna, Dept Med 1, Vienna, Austria
[4] City Hope Comprehens Canc Ctr, Duarte, CA USA
[5] Univ Campania Luigi Vanvitelli, Dept Precis Med, Neapel, Italy
[6] Univ Hosp Leuven, Dept Digest Oncol, Herent, Belgium
[7] Katholieke Univ Leuven, Dept Digest Oncol, Herent, Belgium
[8] Nucleo Pesquisa & Ensino Rede Sao Camilo, Sao Paulo, Brazil
[9] Maria Sklodowska Curie Natl Canc Res Inst, Dept Radiotherapy & Oncol, Warsaw, Poland
[10] Moscow City Oncol Hosp 62, Moscow, Russia
[11] Duna Med Ctr, Med Oncol, Budapest, Hungary
[12] Inst Cancerol, Brest, France
[13] Univ Southern Denmark, Dept Clin Res, Odense, Denmark
[14] Univ Pisa, Dept Translat Res & New Technol, Pisa, Italy
[15] Taiho Oncol Inc, Princeton, NJ USA
[16] Dnipropetrovsk Med Acad, Dept Oncol & Med Radiol, Dnipro, Ukraine
[17] Servier Int Res Inst, Suresnes, France
[18] Univ Paris Cite, Georges Pompidou European Hosp, SIRIC CARPEM, Paris, France
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V1019
引用
收藏
页码：157 / 158
页数：2
相关论文
共 50 条
  • [31] Panitumumab plus trifluridine/tipiracil as third-line anti-EGFR rechallenge therapy in chemo-refractory RAS WT metastatic colorectal cancer: The VELO randomized phase II clinical trial.
    Napolitano, Stefania
    De Falco, Vincenzo
    Martini, Giulia
    Esposito, Lucia
    Famiglietti, Vincenzo
    Martinelli, Erika
    Ciardiello, Davide
    Marrone, Francesca
    Avallone, Antonio
    Cardone, Claudia
    De Stefano, Alfonso
    Montesarchio, Vincenzo
    Zampino, M. Giulia
    Bordonaro, Roberto
    Scartozzi, Mario
    Santini, Daniele
    Di Maio, Massimo
    Ciardiello, Fortunato
    Troiani, Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 129 - 129
  • [32] Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer
    Fumet, Jean-David
    Roussot, Nicolas
    Bertaut, Aurelie
    Limagne, Emeric
    Thibaudin, Marion
    Hervieu, Alice
    Zanetta, Sylvie
    Borg, Christophe
    Senellart, Helene
    Pernot, Simon
    Thuillier, Frederic
    Carnot, Aurelien
    Mineur, Laurent
    Chibaudel, Benoist
    Touchefeu, Yann
    Martin-Babau, Jerome
    Jary, Marine
    Labourey, Jean-Luc
    Rederstorff, Emilie
    Lepage, Come
    Ghiringhelli, Francois
    FUTURE ONCOLOGY, 2024, 20 (38) : 3077 - 3085
  • [33] A phase II study of trifluridine/tipiracil, irinotecan, and bevacizumab in pretreated metastatic colorectal cancer (TABAsCO)
    Gupta, Medhavi
    Fountzilas, Christos
    Vijayvergia, Namrata
    Attwood, Kristopher
    Hochster, Howard S.
    Mukherjee, Sarbajit
    Iyer, Renuka V.
    Boland, Patrick Mckay
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [34] Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study
    Taniguchi, Hiroya
    Yamazaki, Kentaro
    Masuishi, Toshiki
    Kawakami, Takeshi
    Onozawa, Yusuke
    Honda, Kazunori
    Kadowaki, Shigenori
    Narita, Yukiya
    Tsushima, Takahiro
    Hamauchi, Satoshi
    Todaka, Akiko
    Yokota, Tomoya
    Ando, Masashi
    Mori, Keita
    Shirasu, Hiromichi
    Yasui, Hirofumi
    Muro, Kei
    ONCOLOGIST, 2023, : E1108 - E1113
  • [35] Efficacy and safety of trifluridine/tipiracil in combination with bevacizumab in older and younger patients with refractory metastatic colorectal cancer: A subgroup analysis of the phase 3 SUNLIGHT trial.
    Taieb, Julien
    Prager, Gerald W.
    Fakih, Marwan
    Ciardello, Fortunato
    Van Cutsem, Eric
    Elez, Elena
    Cruz, Felipe Melo
    Wyrwicz, Lucjan S.
    Stroyakovskiy, Daniil
    Papai, Zsuzsanna
    Poureau, Pierre-Guillaume
    Liposits, Gabor
    Cremolini, Chiara
    Bondarenko, Igor
    Modest, Dominik Paul
    Roby, Lucas
    Barboux, Valentine
    Amellal, Nadia
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 111 - 111
  • [36] Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer
    Nakanishi, Koki
    Tanaka, Chie
    Kanda, Mitsuro
    Miyata, Kazushi
    Machida, Nozomu
    Sakai, Mitsuru
    Kobayashi, Daisuke
    Teramoto, Hitoshi
    Ishiyama, Akiharu
    Sato, Bin
    Oshima, Takashi
    Kajikawa, Masaki
    Matsushita, Hidenobu
    Ishigure, Kiyoshi
    Yamashita, Katsuya
    Fujitake, Shinichi
    Sueoka, Satoshi
    Asada, Takahiro
    Shimizu, Dai
    Sugita, Shizuki
    Kuwatsuka, Yachiyo
    Maeda, Osamu
    Furune, Satoshi
    Murotani, Kenta
    Ando, Yuichi
    Ebata, Tomoki
    Kodera, Yasuhiro
    NAGOYA JOURNAL OF MEDICAL SCIENCE, 2024, 86 (01): : 43 - 51
  • [37] Impact of KRASG12 mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial
    Tabernero, J.
    Taieb, J.
    Fakih, M.
    Prager, G. W.
    Van Cutsem, E.
    Ciardiello, F.
    Mayer, R. J.
    Amellal, N.
    Skanji, D.
    Calleja, E.
    Yoshino, T.
    ESMO OPEN, 2024, 9 (03)
  • [38] Sequential Treatment with Regorafenib and Trifluridine/Tipiracil ± Bevacizumab in Refractory Metastatic Colorectal Cancer in Community Clinical Practice in the USA
    Ahn, Daniel H.
    Bekaii-Saab, Tanios S.
    Yuan, Chengbo
    Kurtinecz, Milena
    Pan, Xiaoyun
    Vassilev, Zdravko
    Pisa, Federica
    Ostojic, Helene
    CANCERS, 2025, 17 (06)
  • [39] Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer
    Taieb, Julien
    Fakih, Marwan
    Liposits, Gabor
    Prager, Gerald W.
    Van Cutsem, Eric
    Ciardiello, Fortunato
    Amellal, Nadia
    Calleja, Elizabeth
    Liu, Mei
    Roby, Lucas
    Tabernero, Josep
    Andre, Thierry
    FRONTIERS IN ONCOLOGY, 2025, 14
  • [40] Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic Colorectal Cancer: A Multicenter Retrospective Comparative Study
    Bazarbashi, Shouki
    Alkhatib, Radwan
    Aseafan, Mohamed
    Tuleimat, Yasmin
    Abdel-Aziz, Nashwa
    Mahrous, Mervat
    Elsamany, Sherif
    Elhassan, Tusneem
    Alghamdi, Mohammed
    JCO GLOBAL ONCOLOGY, 2024, 10
12345